UBS analyst Joshua Spector lowered the firm’s price target on Xylem (XYL) to $152 from $155 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XYL:
- Xylem price target lowered to $160 from $165 at Oppenheimer
- Xylem assumed with a Hold at Jefferies
- Xylem Authorizes New $1.5 Billion Share Repurchase Program
- Xylem authorizes up to $1.5B share buyback program
- Balancing Near-Term Execution Risks and Long-Term Portfolio Upside: Why Xylem Remains a Hold